Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of...
20 insider purchases on record · latest filing 2025-11-13.
Insiders have also filed 145 sale transactions at EWTX.